28.01
0.60%
-0.17
Handel nachbörslich:
27.98
-0.03
-0.11%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Pfizer Inc. Aktie (PFE) Neueste Nachrichten
Earn $1000 Every Month From These 3 Stocks
The Motley Fool
Stocks Surge On Healthy Earnings Season, Rising Jobless Claims: This Week In The Markets
Benzinga
Pharma Stock Roundup: PFE DMD Study Patient Death, FDA Panel Meet for LLY's Donanemab
Zacks Investment Research
2 Beaten-Down Stocks to Buy and Hold for 10 Years
The Motley Fool
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 5% Dividend Yields
Benzinga
How To Build An 8% Yielding SWAN Portfolio With 10 Blue Chips
Seeking Alpha
2 No-Brainer Dividend Stocks to Buy in May
The Motley Fool
This 6% Yielding Dividend Stock Could Pump Up Your Passive-Income Stream
The Motley Fool
Pfizer: A 6% Yield And At 10-Year Lows
Seeking Alpha
Got $1,000? 3 Dividend Stocks to Buy and Hold Forever
The Motley Fool
Jim Cramer Advises Investors To Brace For Economic Slowdown, Shares Tips To Maintain Balanced Portfolio: 'I'm Not Telling You To Relax'
Benzinga
Pfizer: Solid Earnings, But We're Not Out Of The Woods Yet
Seeking Alpha
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Zacks Investment Research
Pfizer: Ignore The Dead Cat Bounce
Seeking Alpha
3 No-Brainer Stocks to Buy in May
The Motley Fool
Can Pfizer Challenge Lilly and Novo Nordisk in the Obesity Market?
The Motley Fool
3 High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade
The Motley Fool
SCHD: A Must-Have In Every Dividend Portfolio
Seeking Alpha
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
Zacks Investment Research
Here's Why Pfizer (PFE) is a Strong Momentum Stock
Zacks Investment Research
Pfizer Prospects Garner Mixed Sentiment From Analysts: 'Finally, The Pivot Investors Have Been Waiting For'
Benzinga
My Top 5 Favorite High-Yield Dividend Stocks to Buy in May
The Motley Fool
Pfizer's Stock Is a Buy. Here Are Six Reasons Why.
The Motley Fool
Company News for May 2, 2024
Zacks Investment Research
Pfizer (PFE) Q1 2024 Earnings Call Transcript
The Motley Fool
Why Pfizer Stock Blasted More Than 6% Higher Today
The Motley Fool
US Stocks Mixed Ahead Of Fed Meeting, Chipmakers Tumble After AMD Earnings, Bitcoin Sinks: What's Driving Markets Wednesday?
Benzinga
Pfizer (PFE) Q1 Earnings & Sales Top, EPS Guidance Raised
Zacks Investment Research
Pfizer (PFE) Reports Q1 Earnings: What Key Metrics Have to Say
Zacks Investment Research
Pfizer (PFE) Q1 Earnings and Revenues Beat Estimates
Zacks Investment Research
BioNTech (BNTX) to Report Q1 Earnings: Is a Beat in Store?
Zacks Investment Research
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
Zacks Investment Research
Pfizer Sees Less Revenue From Covid-19 Treatments, Stock Faces Headwinds Ahead Of Q1 Earnings
Benzinga
Eli Lilly (LLY) Tops Q1 Earnings Estimates
Zacks Investment Research
5 Top Stocks to Buy in May
The Motley Fool
Why I'm Buying This Beaten-Down, High-Yield Dividend Stock Hand Over Fist
The Motley Fool
Forget Nvidia: Prominent Billionaires Are Selling It and Buying These 2 Ultra-High-Yield Dividend Stocks Instead
The Motley Fool
Is 7%-Yielding Pfizer Stock A Buy On The Dip Before Q1?
Seeking Alpha
Here's How to Play Pfizer (PFE) Stock Ahead of Q1 Earnings
Zacks Investment Research
Why Pfizer (PFE) is a Top Value Stock for the Long-Term
Zacks Investment Research
What Makes Amazon (AMZN) Attractive Ahead of Q1 Earnings?
Zacks Investment Research
3 Beaten-Down Stocks I Wouldn't Touch With a 10-Foot Pole
The Motley Fool
Is Viking Therapeutics Incredibly Undervalued?
The Motley Fool
Wall Street Breakfast: The Week Ahead
Seeking Alpha
3 High-Yield Dividend Stocks That Could Soar 22% to 49%, According to Wall Street
The Motley Fool
3 Dividend Stocks to Buy and Hold for the Next Decade
The Motley Fool
Gear Up for Pfizer (PFE) Q1 Earnings: Wall Street Estimates for Key Metrics
Zacks Investment Research
AbbVie (ABBV) Beats Q1 Earnings and Revenue Estimates
Zacks Investment Research
Want $2,000 in Annual Dividends? Invest $30,000 in These 3 Stocks
The Motley Fool
Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat
Zacks Investment Research
Kapitalisierung:
|
Volumen (24h):